Severe cognitive impairment

SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa

Retrieved on: 
Thursday, December 1, 2022
Science, FIH, Professor, DSMB, RCD, Natural history, ANSM, Food, University, DNA, Epistasis, Gene, IND, University of Pittsburgh Medical Center, Safety, PDE6B, Toys "R" Us, Inc. v. Step Two, S.A, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PDE6A, Retina, Retinitis pigmentosa, Disease, RHO, CTA, IRD, AMD, Research, Quality of life, Severe cognitive impairment, Data monitoring committee, Oxidative stress, AAV, FDA, IRDS, Pharmaceutical industry, Vaccine, RP

SparingVision has also submitted a clinical trial authorisation (CTA) application to the French regulator (ANSM), which is currently under review.

Key Points: 
  • SparingVision has also submitted a clinical trial authorisation (CTA) application to the French regulator (ANSM), which is currently under review.
  • First safety data are anticipated in 2023 and the primary endpoint is expected to be reached in 2025.
  • With over 80 genes involved in RP, each with numerous causative mutations, we need to go beyond the gene-by-gene treatment approach.
  • SPVN06 has the potential to become the universal therapeutic solution that patients need, and we are excited for the next phase of development.

TCN to Host Second Annual C3 Virtual User Group Conference for Contact Center Professionals

Retrieved on: 
Thursday, December 1, 2022
Privacy, Consumer Financial Protection Bureau, Bailey, NBA, Hogan Lovells, Engineering, Conference, TCPA, Telephone Consumer Protection Act of 1991, Microsoft, API, Learning, ACA International, Data management, Analytics, Severe cognitive impairment, TCN, Maintenance, TCN Protocol, Consumer, Q&A, Fortune 500, Integrated Automated Fingerprint Identification System, Data, Automation, C3, Intelligence, ACA, Management, Tutoring, Online shopping

ST. GEORGE, Utah, Dec. 1, 2022 /PRNewswire-PRWeb/ -- TCN, Inc., a global provider of a comprehensive cloud-based call center platform for enterprises, contact centers, BPOs and collection agencies, announced that it will host its second annual C3 Virtual User Group Conference on January 18 and 19, 2023. This event will feature various presentations that aim to educate contact center professionals on the latest industry trends and practical insights into how TCN clients can use its cloud-based platform to improve operations and provide a better customer experience.

Key Points: 
  • ST. GEORGE, Utah, Dec. 1, 2022 /PRNewswire-PRWeb/ -- TCN, Inc. , a global provider of a comprehensive cloud-based call center platform for enterprises, contact centers, BPOs and collection agencies, announced that it will host its second annual C3 Virtual User Group Conference on January 18 and 19, 2023.
  • "We are thrilled to bring back the C3 Virtual User Group Conference again this year," said McKay Bird, marketing director at TCN.
  • The first day of the two-day event will kick off with Thurl Bailey, a retired NBA player and motivational speaker.
  • To help attendees increase proficiency with TCN's call center software, C3 will also offer several product demos and Q&A sessions with TCN executives, engineers, product managers and clients.

HealthWell Foundation Opens Vitamins and Supplements Fund to Assist Individuals Living with Alagille Syndrome

Retrieved on: 
Wednesday, November 30, 2022
Growth, Severe cognitive impairment, Heart, Skin, Itch, Cholestasis, Safety, Vitamin, Genetic disorder, Life, Insurance, Alagille syndrome, Patient, Rickets, Education, Nutrient, Skeleton, Coagulopathy, Charitable organization, Bile, Failure, Quality of life, Jaundice, Malabsorption, Liver, Health insurance, Dietary supplement, Operation

GERMANTOWN, Md., Nov. 30, 2022 /PRNewswire/ -- The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, is proud to announce that it has launched a new fund to provide financial assistance to patients living with Alagille Syndrome. Through the new fund, HealthWell will provide up to $1,500 in financial assistance to eligible patients within the United States and U.S. territories who have annual household incomes up to 500 percent of the federal poverty level to obtain vitamins and supplements for the management of their condition.

Key Points: 
  • Alagille syndrome (ALGS) is a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys.
  • Because the body cannot properly absorb fats and fat-soluble vitamins (vitamins A, D, E, and K), affected children may also experience growth deficiencies and failure to thrive.
  • Vitamins and supplements are a critical component in managing the condition but are often costly and represent a financial hardship for many families," commented Roberta Smith, President, Alagille Syndrome Alliance.
  • To determine eligibility and apply for financial assistance, visit HealthWell's Alagille Syndrome Vitamins and Supplements Fund page.

Canadians are Skipping Regular Eye Exams Despite Available Vision Benefits

Retrieved on: 
Wednesday, November 30, 2022
Eye, Severe cognitive impairment, Diagnosis, Glaucoma, OCT, Health Canada, Risk, Patient, Leger, Friends, Specsavers, Optometry, Disease, Diabetes, Eye disease, AMD, Optical coherence tomography, Family, Habit, Health insurance

The results of a recent Specsavers Canadian Eye Exam Survey, conducted by Leger, included insights into the behaviour of Canadians and their habits when it comes to their eye health.

Key Points: 
  • The results of a recent Specsavers Canadian Eye Exam Survey, conducted by Leger, included insights into the behaviour of Canadians and their habits when it comes to their eye health.
  • One-in-four Canadians who do not wear corrective lenses have not had an eye exam in at least 10 years, including 10% of Canadians who have never had an eye exam.
  • With regular eye exams including Optical Coherence Tomography (OCT) patients can receive comprehensive information about their eye health," says Naomi Barber, Director of Optometry, Specsavers Canada.
  • Fifty-seven percent of Canadians who do not wear glasses say that vision worsening over time would cause them to increase the frequency of seeking eye exams.

Ophthalmologists Report Need for Education and Cooperation Between Treating Physicians and Referrers for Geographic Atrophy, According to Spherix Global Insights

Retrieved on: 
Tuesday, November 29, 2022
Ophthalmology, Louise Ivers, Intravitreal injection, Empathy, Geographic atrophy, Patient, Retina, Optometry, Disease, Research, Severe cognitive impairment, FDA, HIV disease progression rates, Pharmaceutical industry

EXTON, Pa., Nov. 29, 2022 /PRNewswire/ -- Spherix Global Insights ("Spherix") recently surveyed 131 US ophthalmologists (81 of whom personally administer intravitreal injections) and 50 optometrists and followed up with 8 qualitative interviews to assess the current and future treatment paradigm of geographic atrophy (GA). This inaugural wave of research is included in Spherix's Market Dynamix™ service and highlights metrics on patient management, while also delving deeper into the opportunity for agents in development.

Key Points: 
  • GA has long been considered an untreatable condition, with devastating consequences of disease progression (blindness and an inevitable loss of independence) well documented from the ophthalmology community.
  • Additionally, optometrists are less likely than ophthalmologists to believe asymptomatic GA patients will be likely to receive intravitreal injection proactively.
  • Ophthalmologists suggest "empathy for what patients go through with GA" is going to be necessary for referrers to fully understand the appropriate treatment approach.
  • Some respondents speculate that even the retina community will need time to fully understand how and when to treat these patients.

Lighthouse Guild and Bionic Sight Announce Partnership to Expand Treatment Options for People Who Are Blind

Retrieved on: 
Tuesday, November 29, 2022
Lighthouse Guild, Tech, Doctor of Philosophy, Severe cognitive impairment, Scientific American, NBC, Bloomberg, Partnership, Brain, Patient, TED, Retina, Retinitis pigmentosa, Discovery Channel, MD, Cornell University, Discovery, Weill Cornell Medicine, Research, Eye, Management

Bionic Sights technology focuses on restoring sight to patients with advanced stage blindness due to retinal degenerative diseases, such as retinitis pigmentosa .

Key Points: 
  • Bionic Sights technology focuses on restoring sight to patients with advanced stage blindness due to retinal degenerative diseases, such as retinitis pigmentosa .
  • Lighthouse Guild and Bionic Sight have a shared commitment to utilizing technology to transform the lives of people who are blind or visually impaired, said Dr. Nirenberg.
  • This partnership with Bionic Sight is a mission-driven initiative that furthers our commitment to providing the most advanced services and programs.
  • The Lighthouse Guild Technology Center provides people with vision loss access to the latest assistive devices and state-of-the-art technology.

Alimera Highlights Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN® Administration

Retrieved on: 
Tuesday, November 29, 2022
Recurrence, Doctor of Philosophy, Fluocinolone acetonide, Severe cognitive impairment, Steroid, DME, IL-6, FAC, Observational study, IOP, Risk, RTV, Physician, Alimera Sciences, Diabetic retinopathy, MBA, Fatigue, Implant, Retina, Injection, Inflammation, Disease, MD, DR, VEGF, Retinal, Intraocular pressure, Visual acuity, Eye, Safety, Medical device, Pharmaceutical industry, Dentistry, Trosia, Patient, Edema

These results were made available at the annual scientific meeting of The Retina Society held in Pasadena, CA from November 2-5, 2022.

Key Points: 
  • These results were made available at the annual scientific meeting of The Retina Society held in Pasadena, CA from November 2-5, 2022.
  • The PALADIN Study data presented demonstrates the correlation between reduced RTV and better visual acuity, and the value of ILUVIENs CONTINUOUS MICRODOSINGin controlling RTV.
  • Anton Kolomeyer, MD, PhD authored a poster titled, Fluocinolone acetonide and DME An Expert Consensus.
  • Additionally, secondary outcomes confirmed improvement in vision and reduction in treatment burden and retinal thickness variability.

Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

Retrieved on: 
Tuesday, November 29, 2022
Professional Services, Health, Finance, Banking, Optical, Biotechnology, Cantor, Infection, Dermatology, Severe cognitive impairment, Fontainebleau Miami Beach, Auditory neuropathy, Geographic atrophy, Hoffmann-La Roche, Cell, VAC2, Compte rendu, Conference, Lineage Cell Therapeutics, NYSE American, Large-cell lung carcinoma, Therapy, Patient, Medtech, Injury, Annual report, Eastern Time Zone, Research, Ophthalmology, Cantor Fitzgerald, Disease, Direct Corporate Access, Health, Security (finance), AMD, Degenerative disease, Cancer, Roche, TASE, Equity, Medicine, Secondary research, FDA, Pharmaceutical industry, Genentech

The panel will be hosted by Jennifer Kim, Vice President, Equity Research at Cantor Fitzgerald, and the conference is taking place at the Fontainebleau Miami Beach hotel, December 7-8, 2022.

Key Points: 
  • The panel will be hosted by Jennifer Kim, Vice President, Equity Research at Cantor Fitzgerald, and the conference is taking place at the Fontainebleau Miami Beach hotel, December 7-8, 2022.
  • Atrophic AMD is a progressive disease that if left untreated can ultimately rob a person of their vision.
  • The Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech conference will feature one-on-ones with leading companies in the Medical & Aesthetic Dermatology, Ophthalmology & MedTech industries, as well as key opinion leaders in the dermatology and ophthalmology space.
  • Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Retrieved on: 
Monday, November 28, 2022
Marketing, COVID-19, Perforation, Biologically based mental illness, Incidence, Severe cognitive impairment, Mouth ulcer, Food, Hand, IND, Safety, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MSC, Disease, Neurotrophic keratitis, Protease, Security (finance), IgG4-related ophthalmic disease, Scar, Research, Coronavirus, Biologics license application, KALA, Eye, Infection, FDA, BLA, Pharmaceutical industry

ARLINGTON, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for KPI-012 for the treatment of Persistent Corneal Epithelial Defect (PCED). Subject to acceptance of the IND by the FDA, Kala remains on-track to initiate a Phase 2b clinical trial of KPI-012 for PCED in the fourth quarter of 2022. Topline safety and efficacy data from the trial is expected in the first quarter of 2024. If positive, this trial could serve as the first of two pivotal trials needed to support the submission of a Biologics License Agreement (BLA) to the FDA. Following acceptance of the IND for KPI-012 by the FDA, Kala will receive the second tranche from the private placement of securities announced earlier today which, together with current cash on hand, Kala expects will extend its projected cash runway into the first quarter of 2025.

Key Points: 
  • Topline safety and efficacy data from the trial is expected in the first quarter of 2024.
  • If positive, this trial could serve as the first of two pivotal trials needed to support the submission of a Biologics License Agreement (BLA) to the FDA.
  • Persistent corneal epithelial defect, which is defined as a persistent non-healing corneal defect or wound that is refractory to conventional treatments, is a rare disease with an estimated incidence in the United States of 100,000 cases per year.
  • KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received orphan drug designation from the U.S. Food and Drug Administration.

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Retrieved on: 
Monday, November 28, 2022
Marketing, COVID-19, Perforation, United, Biologically based mental illness, Incidence, Severe cognitive impairment, Mouth ulcer, Food, IND, Safety, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disease, Neurotrophic keratitis, Protease, Security (finance), Scar, Sale, Research, Biologics license application, Coronavirus, KALA, Eye, Infection, FDA, BLA, Pharmaceutical industry

Kala intends to use proceeds from the financing to advance the clinical development of KPI-012 for the treatment of PCED, as well as for general corporate purposes.

Key Points: 
  • Kala intends to use proceeds from the financing to advance the clinical development of KPI-012 for the treatment of PCED, as well as for general corporate purposes.
  • Kala is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties.
  • Kala does not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.